Telix Pharmaceuticals (OTCMKTS: TLPPF) is a clinical-stage biotechnology company specializing in the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. The company’s core focus lies in creating theranostic products—agents that combine diagnostic imaging and targeted radiotherapy—to improve patient outcomes across a range of solid tumors. Telix’s proprietary platform enables the labeling of tumor-targeting molecules with medically useful radioisotopes, facilitating precise imaging and delivering therapeutic doses directly to cancerous tissue.
Among its lead programs is TLX591, a prostate-specific membrane antigen (PSMA) targeting radiotracer designed for both imaging and radiotherapy in prostate cancer. Another key asset, TLX250-CDx, is a zirconium-89–labeled antibody for PET imaging of renal cell carcinoma, developed as a companion diagnostic to identify patients most likely to benefit from targeted therapies. Telix is also advancing TLX101, a radioiodinated agent for glioblastoma multiforme, which aims to address a critical unmet need in brain cancer treatment by delivering localized radiation to tumor tissue while sparing healthy brain structures.
Since its foundation in 2015 and subsequent listing on the Australian Securities Exchange in 2018, Telix has expanded its operations across North America, Europe and Asia-Pacific. The company has secured regulatory clearances or breakthrough designations from authorities such as Australia’s Therapeutic Goods Administration (TGA) and the U.S. Food and Drug Administration (FDA) for several of its investigational products. Telix also maintains strategic manufacturing and distribution partnerships to support scalable production of radioisotopes and ensure timely delivery to imaging centers and treatment facilities.
Telix is led by Chief Executive Officer Christian Behrenbruch, who brings extensive experience in radiopharmaceutical development and commercialization, alongside Chief Financial Officer Damien Keown. Under their leadership, the company continues to build a diversified pipeline of precision oncology products, leveraging collaborations with academic institutions and industry partners. Telix’s mission centers on transforming the management of cancer through innovative radiopharmaceutical solutions that integrate diagnosis and therapy in a single, targeted approach.
AI Generated. May Contain Errors.
MarketBeat All Access